Logo image of IBS.LS

IBERSOL SGPS SA (IBS.LS) Stock Fundamental Analysis

ELI:IBS - Euronext Lisbon - PTIBS0AM0008 - Common Stock - Currency: EUR

8.68  +0.04 (+0.46%)

Fundamental Rating

4

IBS gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 55 industry peers in the Hotels, Restaurants & Leisure industry. While IBS seems to be doing ok healthwise, there are quite some concerns on its profitability. IBS has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

IBS had positive earnings in the past year.
IBS had a positive operating cash flow in the past year.
Of the past 5 years IBS 4 years were profitable.
Each year in the past 5 years IBS had a positive operating cash flow.
IBS.LS Yearly Net Income VS EBIT VS OCF VS FCFIBS.LS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M

1.2 Ratios

IBS's Return On Assets of 2.32% is in line compared to the rest of the industry. IBS outperforms 50.91% of its industry peers.
IBS has a Return On Equity (4.95%) which is comparable to the rest of the industry.
IBS has a Return On Invested Capital of 3.03%. This is in the lower half of the industry: IBS underperforms 60.00% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for IBS is significantly below the industry average of 11.55%.
Industry RankSector Rank
ROA 2.32%
ROE 4.95%
ROIC 3.03%
ROA(3y)10.54%
ROA(5y)5.26%
ROE(3y)19.9%
ROE(5y)6.52%
ROIC(3y)4.73%
ROIC(5y)N/A
IBS.LS Yearly ROA, ROE, ROICIBS.LS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40

1.3 Margins

Looking at the Profit Margin, with a value of 3.72%, IBS is in line with its industry, outperforming 50.91% of the companies in the same industry.
In the last couple of years the Profit Margin of IBS has declined.
The Operating Margin of IBS (4.91%) is comparable to the rest of the industry.
IBS's Operating Margin has declined in the last couple of years.
With a Gross Margin value of 48.89%, IBS perfoms like the industry average, outperforming 54.55% of the companies in the same industry.
IBS's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 4.91%
PM (TTM) 3.72%
GM 48.89%
OM growth 3YN/A
OM growth 5Y-6.14%
PM growth 3YN/A
PM growth 5Y-7.85%
GM growth 3Y4.13%
GM growth 5Y-0.15%
IBS.LS Yearly Profit, Operating, Gross MarginsIBS.LS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 40 60

More info and screens

4

2. Health

2.1 Basic Checks

IBS has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
IBS has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for IBS has been increased compared to 5 years ago.
IBS has a worse debt/assets ratio than last year.
IBS.LS Yearly Shares OutstandingIBS.LS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
IBS.LS Yearly Total Debt VS Total AssetsIBS.LS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

An Altman-Z score of 1.94 indicates that IBS is not a great score, but indicates only limited risk for bankruptcy at the moment.
IBS has a better Altman-Z score (1.94) than 65.45% of its industry peers.
The Debt to FCF ratio of IBS is 6.77, which is on the high side as it means it would take IBS, 6.77 years of fcf income to pay off all of its debts.
IBS's Debt to FCF ratio of 6.77 is in line compared to the rest of the industry. IBS outperforms 54.55% of its industry peers.
A Debt/Equity ratio of 0.69 indicates that IBS is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.69, IBS is in the better half of the industry, outperforming 63.64% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.69
Debt/FCF 6.77
Altman-Z 1.94
ROIC/WACC0.48
WACC6.26%
IBS.LS Yearly LT Debt VS Equity VS FCFIBS.LS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M 300M 400M

2.3 Liquidity

IBS has a Current Ratio of 1.38. This is a normal value and indicates that IBS is financially healthy and should not expect problems in meeting its short term obligations.
IBS has a Current ratio of 1.38. This is amongst the best in the industry. IBS outperforms 81.82% of its industry peers.
IBS has a Quick Ratio of 1.28. This is a normal value and indicates that IBS is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.28, IBS is in the better half of the industry, outperforming 78.18% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.38
Quick Ratio 1.28
IBS.LS Yearly Current Assets VS Current LiabilitesIBS.LS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

IBS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -88.97%.
IBS shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -13.58% yearly.
IBS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.51%.
IBS shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -1.46% yearly.
EPS 1Y (TTM)-88.97%
EPS 3YN/A
EPS 5Y-13.58%
EPS Q2Q%12.5%
Revenue 1Y (TTM)10.51%
Revenue growth 3Y13.12%
Revenue growth 5Y-1.46%
Sales Q2Q%16.68%

3.2 Future

Based on estimates for the next years, IBS will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.95% on average per year.
The Revenue is expected to grow by 6.37% on average over the next years.
EPS Next Y4.84%
EPS Next 2Y17.32%
EPS Next 3Y21.79%
EPS Next 5Y17.95%
Revenue Next Year8.97%
Revenue Next 2Y8.19%
Revenue Next 3Y7.92%
Revenue Next 5Y6.37%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IBS.LS Yearly Revenue VS EstimatesIBS.LS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 100M 200M 300M 400M 500M
IBS.LS Yearly EPS VS EstimatesIBS.LS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.5 -0.5 -1

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 21.70, which indicates a rather expensive current valuation of IBS.
IBS's Price/Earnings ratio is a bit cheaper when compared to the industry. IBS is cheaper than 67.27% of the companies in the same industry.
IBS's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 29.35.
With a Price/Forward Earnings ratio of 20.14, IBS is valued on the expensive side.
IBS's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. IBS is cheaper than 61.82% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of IBS to the average of the S&P500 Index (22.10), we can say IBS is valued inline with the index average.
Industry RankSector Rank
PE 21.7
Fwd PE 20.14
IBS.LS Price Earnings VS Forward Price EarningsIBS.LS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

IBS's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. IBS is cheaper than 80.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 8.44
EV/EBITDA N/A
IBS.LS Per share dataIBS.LS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IBS does not grow enough to justify the current Price/Earnings ratio.
A more expensive valuation may be justified as IBS's earnings are expected to grow with 21.79% in the coming years.
PEG (NY)4.48
PEG (5Y)N/A
EPS Next 2Y17.32%
EPS Next 3Y21.79%

More info and screens

6

5. Dividend

5.1 Amount

IBS has a Yearly Dividend Yield of 5.79%, which is a nice return.
Compared to an average industry Dividend Yield of 2.93, IBS pays a better dividend. On top of this IBS pays more dividend than 96.36% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.33, IBS pays a better dividend.
Industry RankSector Rank
Dividend Yield 5.79%

5.2 History

On average, the dividend of IBS grows each year by 31.58%, which is quite nice.
Dividend Growth(5Y)31.58%
Div Incr Years1
Div Non Decr Years1
IBS.LS Yearly Dividends per shareIBS.LS Yearly Dividends per shareYearly Dividends per share 2019 2022 2023 2024 0.2 0.4 0.6

5.3 Sustainability

IBS pays out 122.87% of its income as dividend. This is not a sustainable payout ratio.
The dividend of IBS is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP122.87%
EPS Next 2Y17.32%
EPS Next 3Y21.79%
IBS.LS Yearly Income VS Free CF VS DividendIBS.LS Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M
IBS.LS Dividend Payout.IBS.LS Dividend Payout, showing the Payout Ratio.IBS.LS Dividend Payout.PayoutRetained Earnings

More info and screens

IBERSOL SGPS SA

ELI:IBS (3/7/2025, 7:00:00 PM)

8.68

+0.04 (+0.46%)

Chartmill FA Rating
GICS SectorConsumer Discretionary
GICS IndustryGroupConsumer Services
GICS IndustryHotels, Restaurants & Leisure
Earnings (Last)11-29 2024-11-29/amc
Earnings (Next)N/A N/A
Inst Owners23.23%
Inst Owner ChangeN/A
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap360.31M
Analysts83.33
Price Target12.09 (39.29%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 5.79%
Yearly Dividend0.7
Dividend Growth(5Y)31.58%
DP122.87%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-20.44%
Min EPS beat(2)-25.74%
Max EPS beat(2)-15.13%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)5.23%
Min Revenue beat(2)0.18%
Max Revenue beat(2)10.27%
Revenue beat(4)4
Avg Revenue beat(4)6.97%
Min Revenue beat(4)0.18%
Max Revenue beat(4)10.27%
Revenue beat(8)6
Avg Revenue beat(8)5.69%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.16%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-12.63%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.16%
Valuation
Industry RankSector Rank
PE 21.7
Fwd PE 20.14
P/S 0.79
P/FCF 8.44
P/OCF 4.68
P/B 1.06
P/tB 1.47
EV/EBITDA N/A
EPS(TTM)0.4
EY4.61%
EPS(NY)0.43
Fwd EY4.96%
FCF(TTM)1.03
FCFY11.85%
OCF(TTM)1.86
OCFY21.38%
SpS10.95
BVpS8.22
TBVpS5.89
PEG (NY)4.48
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 2.32%
ROE 4.95%
ROCE 3.84%
ROIC 3.03%
ROICexc 4.07%
ROICexgc 5.24%
OM 4.91%
PM (TTM) 3.72%
GM 48.89%
FCFM 9.4%
ROA(3y)10.54%
ROA(5y)5.26%
ROE(3y)19.9%
ROE(5y)6.52%
ROIC(3y)4.73%
ROIC(5y)N/A
ROICexc(3y)6.92%
ROICexc(5y)N/A
ROICexgc(3y)9.56%
ROICexgc(5y)N/A
ROCE(3y)5.99%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y-20.96%
ROICexc growth 3YN/A
ROICexc growth 5Y-13.96%
OM growth 3YN/A
OM growth 5Y-6.14%
PM growth 3YN/A
PM growth 5Y-7.85%
GM growth 3Y4.13%
GM growth 5Y-0.15%
F-Score6
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity 0.69
Debt/FCF 6.77
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 7.55%
Interest Coverage 250
Cash Conversion N/A
Profit Quality 252.85%
Current Ratio 1.38
Quick Ratio 1.28
Altman-Z 1.94
F-Score6
WACC6.26%
ROIC/WACC0.48
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)12.95%
Cap/Sales(5y)11.86%
Profit Quality(3y)143.97%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-88.97%
EPS 3YN/A
EPS 5Y-13.58%
EPS Q2Q%12.5%
EPS Next Y4.84%
EPS Next 2Y17.32%
EPS Next 3Y21.79%
EPS Next 5Y17.95%
Revenue 1Y (TTM)10.51%
Revenue growth 3Y13.12%
Revenue growth 5Y-1.46%
Sales Q2Q%16.68%
Revenue Next Year8.97%
Revenue Next 2Y8.19%
Revenue Next 3Y7.92%
Revenue Next 5Y6.37%
EBIT growth 1Y-21.52%
EBIT growth 3YN/A
EBIT growth 5Y-7.51%
EBIT Next Year301.66%
EBIT Next 3Y75.66%
EBIT Next 5Y56.64%
FCF growth 1Y-28.97%
FCF growth 3YN/A
FCF growth 5Y20.7%
OCF growth 1Y-29.99%
OCF growth 3Y45.49%
OCF growth 5Y10.5%